Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Abnormal Proliferation02:23

Abnormal Proliferation

4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Unraveling the Role of miR-33a-5p in Bladder Cancer Progression: Clinical Significance and Functional Pathways.

Combinatorial chemistry & high throughput screening·2026
Same author

Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.

Current topics in medicinal chemistry·2026
Same author

CCNJL as a Prognostic Biomarker and Therapeutic Target in Cholangiocarcinoma.

Current medicinal chemistry·2026
Same author

Decoding Sarcoma Drug Resistance: From Molecular Mechanisms to Precision Interventions.

Anti-cancer agents in medicinal chemistry·2026
Same author

Research Progress on Desmoid Tumors: New Perspectives from Molecular Mechanisms to Clinical Management.

Anti-cancer agents in medicinal chemistry·2026
Same author

From Biomarker to Drug Target: Integrating ceRNA Networks and Pharmacogenomics to Reposition C5orf34 in Uterine Corpus Endometrial Cancer Therapy.

Current medicinal chemistry·2026

相关实验视频

Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K

探索MFSD9:从表达模式到LUAD的治疗影响

Qian Wang1, Meijuan Zhang2, Yan Xiang1

  • 1Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Current medicinal chemistry
|July 3, 2025
PubMed
概括

主促进者超级家族域含有蛋白9 (MFSD9) 在肺腺癌 (LUAD) 中过度表达,这表明它是一种潜在的预后生物标志物和治疗点,可以改善患者的治疗结果.

关键词:
肺部腺癌瘤是肺部腺癌.在MFSD9中,MFSD9在MFSD9中生物标志物生物标志物药物敏感性 药物敏感性免疫透 免疫透是什么?预后 预后 预后

更多相关视频

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K
The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.3K

相关实验视频

Last Updated: Sep 17, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

8.0K
Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression
06:03

Orthotopic Transplantation of Syngeneic Lung Adenocarcinoma Cells to Study PD-L1 Expression

Published on: January 19, 2019

17.3K
The Soft Agar Colony Formation Assay
08:01

The Soft Agar Colony Formation Assay

Published on: October 27, 2014

112.3K

科学领域:

  • 在瘤学瘤学.
  • 分子生物学分子生物学
  • 生物信息学是一种生物信息学.

背景情况:

  • 肺腺癌 (LUAD) 是癌症相关死亡的主要原因.
  • 确定新的生物标志物和治疗点对于改善LUAD患者的预后和治疗策略至关重要.

研究的目的:

  • 调查LUAD中主要促进者超级家族域含蛋白9 (MFSD9) 的作用.
  • 评估MFSD9作为潜在的预后生物标志物和LUAD治疗点.

主要方法:

  • 利用癌症基因组图谱 (TCGA) 数据集对LUAD中MFSD9表达的全面分析.
  • 与临床结果,免疫透,瘤突变负担 (TMB),微卫星不稳定性 (MSI) 和药物敏感性相关的MFSD9表达.
  • 使用人类蛋白质图集 (HPA),基因表达综合 (GEO) 数据库和qRT-PCR验证的结果.

主要成果:

  • 在LUAD中,MFSD9显著过度表达,与较差的整体存活率 (OS) 和无进展存活率 (PFS) 相关.
  • 在LUAD中,MFSD9作为一个独立的预后因素.
  • MFSD9的表达与免疫细胞透,免疫检查点基因,TMB,MSI,mRNA表达-茎度指数 (mRNAsi) 相相关,反之,与对齐戈斯波林A和洛瓦斯塔丁的敏感性相相关.

结论:

  • MFSD9在LUAD中显示出作为预后生物标志物和治疗点的潜力.
  • 在免疫调节中MFSD9的参与表明其在LUAD的免疫治疗策略中的实用性.
  • 建议进行进一步的功能验证,以探索MFSD9在LUAD治疗中的临床应用.